These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26416620)

  • 1. Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade.
    Padfield GJ; AlAhmari L; Lieve KV; AlAhmari T; Roston TM; Wilde AA; Krahn AD; Sanatani S
    Heart Rhythm; 2016 Feb; 13(2):609-13. PubMed ID: 26416620
    [No Abstract]   [Full Text] [Related]  

  • 2. Wide Complex Tachycardia in a Patient With a History of Atrial Fibrillation.
    Hegde S; Kumar V
    JAMA Intern Med; 2016 Mar; 176(3):386-8. PubMed ID: 26784121
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and efficacy of flecainide for patients with catecholaminergic polymorphic ventricular tachycardia: A systematic review and meta-analysis.
    Wang G; Zhao N; Zhong S; Wang Y; Li J
    Medicine (Baltimore); 2019 Aug; 98(34):e16961. PubMed ID: 31441899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
    Watanabe H; van der Werf C; Roses-Noguer F; Adler A; Sumitomo N; Veltmann C; Rosso R; Bhuiyan ZA; Bikker H; Kannankeril PJ; Horie M; Minamino T; Viskin S; Knollmann BC; Till J; Wilde AA
    Heart Rhythm; 2013 Apr; 10(4):542-7. PubMed ID: 23286974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of flecainide in a patient with catecholaminergic polymorphic ventricular tachycardia.
    Biernacka EK; Hoffman P
    Europace; 2011 Jan; 13(1):129-30. PubMed ID: 20798117
    [No Abstract]   [Full Text] [Related]  

  • 6. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
    Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
    Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.
    Yang PC; Moreno JD; Miyake CY; Vaughn-Behrens SB; Jeng MT; Grandi E; Wehrens XH; Noskov SY; Clancy CE
    J Physiol; 2016 Feb; 594(3):567-93. PubMed ID: 26515697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term flecainide therapy in type 3 long QT syndrome.
    Chorin E; Taub R; Medina A; Flint N; Viskin S; Benhorin J
    Europace; 2018 Feb; 20(2):370-376. PubMed ID: 28339995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Focus on Pharmacological Management of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Claudio B; Alice M; Daniel S
    Mini Rev Med Chem; 2018; 18(6):476-482. PubMed ID: 28685702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia.
    Leren IS; Saberniak J; Majid E; Haland TF; Edvardsen T; Haugaa KH
    Heart Rhythm; 2016 Feb; 13(2):433-40. PubMed ID: 26432584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.
    Bergeman AT; Lieve KVV; Kallas D; Bos JM; Rosés I Noguer F; Denjoy I; Zorio E; Kammeraad JAE; Peltenburg PJ; Tobert K; Aiba T; Atallah J; Drago F; Batra AS; Brugada R; Borggrefe M; Clur SB; Cox MGPJ; Davis A; Dhillon S; Etheridge SP; Fischbach P; Franciosi S; Haugaa K; Horie M; Johnsrude C; Kane AM; Krause U; Kwok SY; LaPage MJ; Ohno S; Probst V; Roberts JD; Robyns T; Sacher F; Semsarian C; Skinner JR; Swan H; Tavacova T; Tisma-Dupanovic S; Tfelt-Hansen J; Yap SC; Kannankeril PJ; Leenhardt A; Till J; Sanatani S; Tanck MWT; Ackerman MJ; Wilde AAM; van der Werf C
    Circulation; 2023 Dec; 148(25):2029-2037. PubMed ID: 37886885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
    Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
    Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxic Effects of Flecainide in a Patient With Kidney Failure and Tachyarrhythmia.
    Liu JS; Fan EH
    JAMA Intern Med; 2021 Nov; 181(11):1516-1518. PubMed ID: 34515729
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
    Kannankeril PJ; Moore JP; Cerrone M; Priori SG; Kertesz NJ; Ro PS; Batra AS; Kaufman ES; Fairbrother DL; Saarel EV; Etheridge SP; Kanter RJ; Carboni MP; Dzurik MV; Fountain D; Chen H; Ely EW; Roden DM; Knollmann BC
    JAMA Cardiol; 2017 Jul; 2(7):759-766. PubMed ID: 28492868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Irregular Wide Complex Tachycardia.
    Watts TE; McElderry HT; Kay GN
    Circulation; 2017 Aug; 136(8):773-775. PubMed ID: 28827222
    [No Abstract]   [Full Text] [Related]  

  • 16. Catecholaminergic polymorphic ventricular tachycardia.
    Leenhardt A; Denjoy I; Guicheney P
    Circ Arrhythm Electrophysiol; 2012 Oct; 5(5):1044-52. PubMed ID: 23022705
    [No Abstract]   [Full Text] [Related]  

  • 17. Transplacental flecainide therapy in the treatment of fetal supraventricular tachycardia.
    D'Souza D; MacKenzie WE; Martin WL
    J Obstet Gynaecol; 2002 May; 22(3):320-2. PubMed ID: 12521516
    [No Abstract]   [Full Text] [Related]  

  • 18. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.
    van der Werf C; Kannankeril PJ; Sacher F; Krahn AD; Viskin S; Leenhardt A; Shimizu W; Sumitomo N; Fish FA; Bhuiyan ZA; Willems AR; van der Veen MJ; Watanabe H; Laborderie J; Haïssaguerre M; Knollmann BC; Wilde AA
    J Am Coll Cardiol; 2011 May; 57(22):2244-54. PubMed ID: 21616285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tachycardia with wide QRS. Limitations of electrocardiographic criteria in patients treated with anti-arrhythmia agents].
    Le Davay M; Victor J; Dupuis JM; Merheb M; Tran P; Tadeï A
    Ann Cardiol Angeiol (Paris); 1994 May; 43(5):253-5. PubMed ID: 8074416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brugada phenocopy with a flecainide overdose: a pharmacological dose effect?
    Chubb H; Cooklin M; Rosenthal E
    J Cardiovasc Electrophysiol; 2014 May; 25(5):547-548. PubMed ID: 24303843
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.